Whitepaper: Why CE Marking Is Just the Starting Line

Between approval and commercial traction

Germany's MedTech market exceeds €41 billion, making it Europe's largest national market. International manufacturers who treat CE marking under the Medical Device Regulation (MDR) as the endpoint often discover that regulatory approval is where the real planning begins.

Five interdependent challenges stand between certification and commercial traction:

A highly fragmented hospital IT landscape
Regulatory requirements that extend well beyond MDR
Localization demands that go deeper than translation
Market access pathways that require local reference installations
Dual compliance under MDR and the EU Artificial Intelligence Act for devices with AI components

This whitepaper maps all five dimensions, the strategic decisions they require, and the patterns that reliably delay market entry by 12 months or more.

What this whitepaper covers

Germany's complexity follows recognizable patterns. The manufacturers who navigate it successfully are not necessarily the ones with the largest resources. They are the ones who plan for all five dimensions from the start, rather than discovering each one after launch.

How Germany's hospital IT landscape works:
No single Hospital Information System (HIS) platform covers more than approximately 40% of hospitals, and the country-specific FHIR interoperability standard (ISiK) adds requirements that a standard FHIR R4-compatible product does not automatically meet.
Which regulatory requirements apply beyond MDR:
Including Germany's national implementation law (MPDG), the mandatory EUDAMED registration starting May 2026, and a layered data protection regime under GDPR, 16 state laws, and ecclesiastical law affecting roughly 30% of hospital beds.
Why pilot projects are a commercial prerequisite:
Group Purchasing Organizations (GPOs) controlling access to more than 1,500 hospitals require local clinical evidence and reference installations before entering framework agreements.
What the EU AI Act (Regulation 2024/1689) means for medical devices with AI components:
Why MDR and AI Act compliance must be planned as a single, integrated process to avoid redundant documentation and avoidable delays during Notified Body interactions.
A phased 18-month market entry roadmap:
With readiness checkpoints at each stage, a decision framework for choosing between building local capabilities in-house, working with a distributor, or pursuing a hybrid partnership model, and a structured overview of typical cost drivers.

It is written for decision-makers at international MedTech companies planning market entry in Germany: CTOs, Regulatory Affairs managers, and business development leads who need a structured overview of what market entry requires beyond CE certification. The content addresses both the strategic level and the operational decisions that follow from it.
It covers five dimensions of market entry complexity, a decision framework for choosing between in-house build, distributor, and hybrid partnership models, a phased 18-month roadmap with specific readiness checkpoints, and a breakdown of the most common mistakes that cause delays and cost overruns. The final section describes what a local specialist partner can realistically contribute to each dimension.
The whitepaper is 19 pages. It includes an executive summary and a key-takeaways section at the front, so you can assess relevance quickly. Each chapter is self-contained, meaning you can go directly to the dimensions most relevant to your current planning stage without reading end to end.
Immediately after submitting the form, you will be redirected to a page with the download link.

Whitepaper: Why CE Marking Is Just the Starting Line

Between approval and commercial traction

What this whitepaper covers

Request whitepaper

FAQ